All In Biotech

Drug Trial Radar · NCT04921527

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

454

Planned (sponsor's estimate)

Start

Dec 20, 2021

Primary completion

Dec 31, 2024

Study completion Jul 31, 2025

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Jun 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.

Conditions

  • Ovarian Cancer
  • Relapsed or Refractory
  • Chiauranib
  • Paclitaxel

Interventions

  • chiauranibDrug

    50mg orally once daily

  • PlaceboDrug

    50mg orally once daily

  • PaclitaxelDrug

    at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival (PFS)Time frame: assessed up to 1 years
  2. overall survival (OS)Time frame: assessed up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.